NeuroBo Pharmaceuticals’ Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models
- Tuesday, June 27, 2023, 7:01
- Finance
- Add a comment
Preclinical Data Also Show DA-1726 Effectively Reduces Body Weight and Glycemic Control Data Presented in One ePoster Theater Discussion and Two General Poster Presentations at the American Diabetes Association 83rd Scientific Sessions BOSTON, June 27, 2023 /PRNewswire/ — NeuroBo…
About the Author
adminasapcorp has written 39023 stories on this site.